Central Nervous System Diseases  >>  Semprana (dihydroergotamine oral inhalation)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Semprana (dihydroergotamine oral inhalation) / AbbVie
FREEDOM301, NCT00623636: Phase 3 Study of MAP0004 in Adult Migraineurs

Checkmark FREEDOM-301
Feb 2013 - Feb 2013: FREEDOM-301
Checkmark Painweek 2012
Sep 2012 - Sep 2012: Painweek 2012
Completed
3
902
US
MAP0004, Placebo
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Migraine Disorders
12/10
01/11

Download Options